Quest Diagnostics Q3 revenue beats estimates on higher demand

Quest Diagnostics

21/10/2025 11:54

Overview

Quest Diagnostics Q3 revenue rises 13.1%, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company raises full-year 2025 guidance, indicating confidence in continued growth

Outlook

Company raises full-year 2025 net revenue guidance to $10.96 bln-$11.00 bln

Quest Diagnostics expects full-year adjusted EPS between $9.76 and $9.84

Company anticipates cash from operations of approximately $1.8 bln for 2025

Result Drivers

ORGANIC AND ACQUISITION GROWTH - Revenue growth driven by 6.8% organic growth and contributions from acquisitions

COREWELL JOINT VENTURE - Agreement with Corewell Health to establish a lab services joint venture in Michigan

CONSUMER CHANNEL EXPANSION - Growth in consumer channel as Quest builds presence as preferred lab engine inside top health and wellness brands

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$2.81 bln
$2.73 bln (13 Analysts)
Q3 Adjusted EPS
Beat
$2.60
$2.50 (15 Analysts)
Q3 EPS
$2.16
Q3 Net Income
$245 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Quest Diagnostics Inc is $190.50, about 0% above its October 20 closing price of $190.41

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nPn26lcyTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)